Senzime Valuation
Is SNZZ.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SNZZ.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SNZZ.F ($0.55) is trading above our estimate of fair value ($0.16)
Significantly Below Fair Value: SNZZ.F is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SNZZ.F?
Key metric: As SNZZ.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is SNZZ.F's PS Ratio? | |
|---|---|
| PS Ratio | 11.8x |
| Sales | SEK 55.29m |
| Market Cap | SEK 650.55m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 11.3x |
| Enterprise Value/EBITDA | -4.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does SNZZ.F's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 6.7x | ||
ECOR electroCore | 3.2x | 27.6% | US$74.4m |
HYPR Hyperfine | 5.5x | 21.0% | US$74.0m |
LUCD Lucid Diagnostics | 13.2x | 54.3% | US$54.4m |
ZOM Zomedica | 4.7x | 25.2% | US$127.2m |
SNZZ.F Senzime | 11.8x | 71.9% | US$650.5m |
Price-To-Sales vs Peers: SNZZ.F is expensive based on its Price-To-Sales Ratio (11.8x) compared to the peer average (6.7x).
Price to Sales Ratio vs Industry
How does SNZZ.F's PS Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Sales vs Industry: SNZZ.F is expensive based on its Price-To-Sales Ratio (11.8x) compared to the US Medical Equipment industry average (3.3x).
Price to Sales Ratio vs Fair Ratio
What is SNZZ.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 11.8x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate SNZZ.F's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | n/a | US$1.13 0% | 2.0% | US$1.15 | US$1.11 | n/a | 2 |
| Nov ’25 | US$0.59 | US$1.15 +94.6% | 2.0% | US$1.17 | US$1.12 | n/a | 2 |
| Oct ’25 | n/a | US$1.21 0% | 2.0% | US$1.24 | US$1.19 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Lantheus Holdings
US$6.3b
Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
LNTH
US$89.53
7D
12.7%
1Y
29.8%
Elevance Health
US$94.5b
Operates as a health benefits company in the United States.
ELV
US$401.96
7D
2.0%
1Y
-15.5%
Centene
US$31.0b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
CNC
US$60.00
7D
3.8%
1Y
-17.8%